Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort

Vaccines are the most effective means to prevent the potentially deadly effects of SARS-CoV-2 infection, but not all vaccinated individuals gain the same degree of protection. Patients undergoing chronic immunosuppressive therapy due to autoimmune diseases or liver transplants, for example, may show...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Erika Zecca, Manuela Rizzi, Stelvio Tonello, Erica Matino, Martina Costanzo, Eleonora Rizzi, Giuseppe Francesco Casciaro, Giulia Francesca Manfredi, Antonio Acquaviva, Ileana Gagliardi, Elisa Calzaducca, Venkata Ramana Mallela, Davide D’Onghia, Rosalba Minisini, Mattia Bellan, Luigi Mario Castello, Francesco Gavelli, Gian Carlo Avanzi, Filippo Patrucco, Annalisa Chiocchetti, Mario Pirisi, Cristina Rigamonti, Daniele Lilleri, Daniele Sola, Pier Paolo Sainaghi
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2022-08-01
Rangatū:	Viruses
Ngā marau:	anti-SARS-CoV-2 vaccination immunosuppressive therapy mycophenolate calcineurin inhibitors autoimmune diseases liver transplant
Urunga tuihono:	https://www.mdpi.com/1999-4915/14/8/1766
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!